BrightSpring Health Services Inc. Common Stock (BTSG)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business that earns high returns on capital and can defend its position. BrightSpring is a home and community-based healthcare platform, with pharmacy and provider services for Medicare, Medicaid and insured patients. The trajectory is real. Filed revenue rose from $7.7B in FY2023 to $10.1B in FY2024 and $12.9B in FY2025. Net income went from -$154.6M in FY2023 to -$18.1M in FY2024 to $190.7M in FY2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3.9B, net income $84.3M and diluted EPS $0.38, versus revenue $3.1B, net income $28.2M and diluted EPS $0.13 in fiscal Q2 2025, the quarter ended 2025-06-30. That is a genuine turnaround, and FairStock's Lynch category of TURNAROUND fits, based on returning to profit after losses within the last three years.

In plain English: BrightSpring runs home and community healthcare services, including pharmacy and provider services for Medicare, Medicaid, and insured patients. Sales are growing quickly and the company has moved from losses to profits, but profit margins are thin and debt is high compared with its equity. At the recent price, the stock looks expensive compared with its earnings and book value, so the business is improving while the price looks rich.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer